TEST:

MSC miRNA test

"AccuStem Sciences, Inc...are pleased to announce the expansion of their strategic partnership to include the commercialization of the MSC test for lung cancer screening. This collaboration aims to enhance the accuracy of lung nodule stratification identified via low-dose computed tomography (LDCT), thereby improving patient outcomes and reducing healthcare costs....Under the expanded agreement, AccuStem and EmeritusDX will embark on operational deployment of the MSC test, with plans for a launch into US clinics in 2026. In parallel, both companies will pursue reimbursement strategies that support broader access to MSC for the 1.6 million patients diagnosed annually with lung nodules in the United States."

"AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced a development agreement to access blood samples from the multi-institutional, prospective, randomized Rete Italiana di Screening Polmonare (RISP) clinical trial. This study is currently enrolling patients across a clinical network of 18 centers in Italy, and will further demonstrate the impact of AccuStem’s microRNA Signature Classifier (MSC) test in the lung cancer screening setting. The agreement will also provide statistical and analytical support and subject matter expertise to AccuStem to establish and commercialize the MSC test in the US."

"AccuStem Sciences...announces plans to launch its microRNA Signature Classifier (MSC) blood test for use in the more than 1.6 million US patients diagnosed each year with nodules as part of current lung cancer screening protocols. The company believes it will be able to further expand the use of the test to all of the 15 million at-risk patients who qualify for lung cancer screening annually in the US."